Henry Schein, Inc. has just announced the successful completion of a $250 million strategic investment by funds affiliated with KKR, a leading global investment firm. This investment has resulted in KKR becoming the holder of approximately 12% of the common shares of Henry Schein. In connection with this transaction, William K. "Dan" Daniel, executive advisor to KKR and former executive vice president of Danaher Corporation, has officially joined Henry Schein's board of directors as an independent director.
Max Lin, partner at KKR and leader of the firm's health care industry team in the Americas, had already become a member of Henry Schein's board of directors on May 2, 2025. Both Max Lin and Dan Daniel have been appointed to various committees within the board, leveraging their extensive experience in the health care and industrial sectors.
Henry Schein, a Fortune 500 company and a member of the S&P 500® index, operates through a centralized and automated distribution network, offering a selection of more than 300,000 branded products and Henry Schein corporate brand products in its distribution centers. The company's sales reached $12.7 billion in 2024 and have grown at a compound annual rate of approximately 11.2% since Henry Schein became a public company in 1995.
The strategic investment by KKR and the appointment of Dan Daniel to the board of directors mark an exciting next chapter for Henry Schein. The company's Chairman of the Board and Chief Executive Officer, Stanley M. Bergman, expressed his pleasure in welcoming Max and Dan to the board, highlighting their deep experience in health care, operations, and strategic growth. This move is expected to be invaluable as the company continues executing on its bold+1 strategy and creating long-term value for its stakeholders. Following these announcements, the company's shares moved 0.71%, and are now trading at a price of $72.05. Check out the company's full 8-K submission here.
